Role of the advanced glycation end products receptor in Crohn’s disease inflammation

Table 1 Demographic and clinical features of Crohn’s disease patients n (%)

Characteristics	A series (n = 20)	B series (n = 14)
Sex
Male	12	6
Female	8	8
Age (yr)
Median (range)	41 (25-61)	40 (21-68)
BMI (kg/m2)
Median (range)	25.5 (20-30)	20.7 (17.2-21.9)
Disease duration (mo)
Median (range)	75 (1-485)	64 (24-360)
Disease location1
L1	14	5
L2	1	2
L3	4	7
L4	None	None
L1-L4	1	None
Disease behavior1
B1	None	6
B2	11	2
B2-B3	8	6
B3	1	None
CDAI
Median (range)	250 (151-537)	244 (141-296)
Current therapies
Patients n
Mesalazine	8 (40)	3 (21.43)
Steroids	2 (10)	3 (21.43)
IS	3 (15)	3 (21.43)
IS + mesalazine	1 (5)	2 (14.29)
Steroids + mesalazine	1 (5)	1 (7.14)
Infliximab	4 (20)	2 (14.29)
IS + infliximab	1 (5)	0

¹Montreal classification[17]. BMI: Body mass index; CDAI: Crohn’s disease activity index; IS: Immunosuppressors.

Table 2 Receptor for the advanced glycation end products expression in Crohn’s disease diseased areas vs control tissues n (%)

Score	Patients	Controls	P value
Grading (epithelium)			0.001
I	2 (20)	8 (80)
II	6 (86)	1 (14)
III	6 (100)	0 (0)
Grading (lamina propria)			0.021
I	7 (44)	9 (56)
II	2 (100)	0 (0)
III	4 (100)	0 (0)
Intensity (epithelium)			0.480
0	2 (67)	1 (33)
1	3 (43)	4 (57)
2	9 (69)	4 (31)
Intensity (lamina propria)			0.260
0	4 (50)	4 (50)
1	4 (50)	4 (50)
2	5 (83)	1 (17)
Epithelial positive cells	% (median: 25th-75th)		0.008
	55 (20-70)	5 (5-5)
Lamina propria positive cells	n/10 hpf (median: 25th-75th)		0.030
	5 (1-15)	1 (0-2)

Table 3 Receptor for the advanced glycation end products expression in Crohn’s disease non-diseased areas vs control tissues n (%)

Score	Patients	Controls	P value
Grading (epithelium)			0.091
I	9 (53)	8 (47)
II	5 (83)	1 (17)
III	2 (100)	0 (0)
Grading (lamina propria)			0.025
I	9 (50)	9 (50)
II	6 (100)	0 (0)
III	1 (100)	0 (0)
Intensity (epithelium)			0.210
0	5 (83)	1 (17)
1	7 (64)	4 (36)
2	4 (50)	4 (4)
Intensity (lamina propria)			0.490
0	4 (50)	4 (50)
1	11 (73)	4 (27)
2	1 (50)	1 (50)
Epithelial positive cells	% (median: 25th-75th)		0.530
	5 (0-55)	5 (5-5)
Lamina propria positive cells	n/10 hpf (median: 25th-75th)		0.079
	4 (0-10)	1 (0-2)

Table 4 Receptor for the advanced glycation end products expression in diseased vs non-diseased areas in Crohn’s disease patients n (%)

Score	Diseased	Non-diseased	P value
Grading (epithelium)			0.17
I	5 (71)	2 (29)
II	4 (44)	5 (56)
III	1 (25)	3 (75)
Grading (lamina propria)			0.53
I	6 (55)	5 (45)
II	3 (75)	1 (25)
III	1 (25)	3 (75)
Intensity (epithelium)			0.37
0	3 (60)	2 (40)
1	4 (67)	2 (33)
2	3 (33)	6 (67)
Intensity (lamina propria)			0.15
0	2 (40)	3 (60)
1	7 (70)	3 (30)
2	1 (25)	3 (75)
Epithelial positive cells	% (median: 25th-75th)		0.24
	12.50 (0-50)	40 (20-60)
Lamina propria positive cells	n/10 hpf (median: 25th-75th)		0.24
	4 (1-13)	5 (1-15)